PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions

British Journal of Cancer

Volumn 113, Issue S1, 2015, Pages S10-S16

  Ledermann, Jonathan A ^a   El Khouly, Fatima ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

BRCA; Olaparib; ovarian cancer; PARP inhibitor; PFS; TFST; TSST

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUPARLISIB; CARBOPLATIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; RUCAPARIB;

ADVERSE DRUG REACTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; CLINICAL DECISION MAKING; CONSTIPATION; DIARRHEA; DISEASE COURSE; DOUBLE STRANDED DNA BREAK; DRUG APPROVAL; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EUROPE; FATIGUE; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; MAINTENANCE THERAPY; NAUSEA; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMBINATION REPAIR; RECURRENT DISEASE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; UNITED STATES; VOMITING; DECISION MAKING; FEMALE; INFORMED CONSENT; METABOLISM; OVARIAN NEOPLASMS;

DECISION MAKING; FEMALE; HUMANS; INFORMED CONSENT; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 84950124151     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.395     Document Type: Review

References (34)

1. American Cancer Society (2013) Cancer Facts & Figures 2013 http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf.
2. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26: 3785-3790.
3. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245-251.
4. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
5. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
6. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, Sessa C, Castiglione M. ESMO Guidelines Working Group (2010) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5): v23-v30.
7. de Jonge MJA, van Herpen C, Gietema JA, Shepherd S, Koornstra R, Jager A, Den Hollander M, Dunbar M, Hetman R, Serpenti C, Xiong H, Zhu M, Giranda VL (2014) A study of ABT-767 in advanced solid tumors with BRCA 1 and BRCA 2 mutations and high grade serous ovarian, fallopian tube, or primary peritoneal cancer. Ann Oncol 25(Suppl4): iv150 (abst 452P).
8. Dougherty B, Ledermann J, Lai Z, Robertson JD, Ho T, Hodgson DR, O'Connor MJ, Fielding A, Hawryluk MJ, Brennan T, Yelensky R, Sun J, Barrett CJ (2014) Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC). J Clin Oncol 32: abst 5536.
9. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
10. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403.
11. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
12. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB (2010) Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28: 2512-2519.
13. Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC. Gynecologic Cancer InterGroup (2011) Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 21: 771-775.
14. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P (2007) Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 14: 195-208.
15. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12: 852-861.
16. Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A. AGO and GINECO study group (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 23: 2605-2612.
17. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmanã J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM (2015) Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation. J Clin Oncol 33: 244-250.
18. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J, Kaufman B (2012) Phase II, openlabel, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30: 372-379.
19. Kristeleit R, Shapira-Frommer R, Burris H, Patel MR, Lorusso PM, Oza AM, Balmanã J, Domchek SM, Chen L, Montes A, Plummer R, Arkenau H, Maloney L, Dominy E, Shapiro G (2014) Phase 1/2 study of oral rucaparib: Updated phase 1 and preliminary phase 2 results. Ann Oncol 25(Suppl 4): iv307 (abst 882PD).
20. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote IB, Rustin GJS, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei DE, Fielding A, Spencer S, Bennet B, Parry D, Matulonis U (2014a) Health-related quality of life (HRQoL) during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) and a BRCA mutation (BRCAm). Ann Oncol 25(Suppl 4): iv305 (abst 885P).
21. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366: 1382-1392.
22. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U (2014b) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15: 852-861.
23. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. ESMO Guidelines Working Group (2013) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6): vi24-vi32.
24. Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC (2014) Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 106: 089.
25. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA (2014) Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 15: 1207-1214.
26. Matulonis U, Harter P, Gourley C, Friedlander M, Vergote IB, Rustin G, Fielding A, Spencer S, Ho TW, Ledermann JA (2015) Analysis of intermediate clinical endpoints from a phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) [abstract no. 132]. Gynecol Oncol 133(Suppl 1): 54-55.
27. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66: 8109-8115.
28. McNeish I, Coleman RL, Oza AM, Konecny GE, O'Malley D, Kichenadasse G, Scott C, Oaknin A, Floquet A, Park D, Brenton J, Lin K, Shetty S, Giordano H, Raponi M, Rolfe L, Swisher E (2014) Preliminary results of ARIEL2, a phase 2 open-label study to identify ovarian cancer patients likely to respond to rucaparib. Ann Oncol 25(Suppl 4): iv305 (abst 883PD).
29. National Cancer Institute (2014) Ovarian epithelial cancer treatment (PDQs): recurrent or persistent ovarian epithelial cancer treatment. Available at http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/HealthProfessional/page6.
30. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Spacek J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16: 87-97.
31. Plummer R, Dua D, Cresti N, Suder A, Drew Y, Prathapan V, Steohens P, Thornton J, Heras BDL, Ink B, Lee L, Matijevic M, McGrath S, Sarker D (2014a) Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma. Ann Oncol 25(Suppl 4): iv151 (abst 453P).
32. Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, Brown PD, Campone M (2014b) Phase 1 dose-escalation study of the PA RP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemother Pharmacol 74: 257-265.
33. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 doseescalation trial. Lancet Oncol 14: 882-892.
34. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9-29.